<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399306</url>
  </required_header>
  <id_info>
    <org_study_id>scch2015001</org_study_id>
    <nct_id>NCT02399306</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Study to Compare Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Cancer Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, prospective, multicenter study. The aim of this study was to compare
      the changes of body weight,survival,toxicity,quality of life and opportunistic infection
      frequency in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma between and after
      chemoradiotherapy with or without enteral nutrition therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Weight Changes</measure>
    <time_frame>before radiotherapy and 1，3，6，9，12 months after the radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life（QOL）</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Quality of life (QOL) as measured by European Organization for Research and Treatment of Cancer quality of life questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>grade 3-5 adverse events(CTCAE v3.0)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Grade 3-5 adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0，such as esophagitis、pneumonitis and hematologic toxicity</description>
  </other_outcome>
  <other_outcome>
    <measure>biology (C-reactive protein, albumin, haemoglobin, creatinine clearance)</measure>
    <time_frame>up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>opportunistic infection frequency</measure>
    <time_frame>up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>immunological function （immunoglobulin G ）</measure>
    <time_frame>up to 1 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Enteral Nutrition Therapy</condition>
  <condition>Chemoradiotherapy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemoradiotherapy with Enteral Nutrition intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nutrison</intervention_name>
    <description>Enteral nutrition intervention：nutrison，15-25kcal/kg/d，according to the eating situation of patients，tube feeding or oral</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.
Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, cisplatin</intervention_name>
    <description>Concurrent chemotherapy：docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 75 years old,male or female

          -  Pathologically or cytologically proven thoracic middle-lower esophageal squamous cell
             carcinoma

          -  Clinical stage II or stage III

          -  PG-SGA：Class B（score 2-8）Class C（score ≧9)

          -  Primary tumors can be measured

          -  Karnofsky score &gt;70

          -  Estimated life expectancy of at least 12 weeks

          -  Reproductive age women should ensure that before entering the study period
             contraception

          -  Hemoglobin≥90.0g/dL,white blood cell count（WBC）≥ 4000 cells/mm³,Platelet count≥100,000
             cells/mm³

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times upper
             limit of normal,bilirubin normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Patients have good compliance to treatment and follow-up of acceptance

          -  Forced expiratory volume in one second（FEV1） ≥ 1.5 litre or ≥ 75% of the reference
             value

          -  Considered operable (i.e. appropriate organ functions and ability to undergo general
             anesthesia)

          -  No severe or uncontrolled cardiovascular disease

          -  No active uncontrolled infection

        Exclusion Criteria:

          1. Patients with severely bowel function impaired or can not tolerate enteral nutrition

          2. Patients with serious gastrointestinal obstruction, be unable to take food by mouth
             and can not / do not want to a feeding tube inserted

          3. Patients have no risk of malnutrition

          4. Patients who have severe vomiting, gastrointestinal bleeding, intestinal obstruction

          5. Patients can not tolerate chemotherapy

          6. Patients who have distant metastasis

          7. The primary tumor or lymph node already received surgical treatment (except for
             biopsy);

          8. Patient who received radiotherapy for primary tumor or lymph node;

          9. Patient who received the the epidermal growth factor targeted therapy;

         10. Patient who received chemotherapy or immunotherapy;

         11. Patient who suffered from other malignant tumor;

         12. Patient who have taken other drug test within 1 month;

         13. Pregnant woman or Lactating Women and Women in productive age who refuse to take
             contraception in observation period;

         14. Subject with a severe allergic history or idiosyncratic;

         15. Subject with severe pulmonary and cardiopathic disease history;

         16. Refuse or incapable to sign the informed consent form of participating this trial;

         17. Drug abuse or alcohol addicted;

         18. Subject with a Personality or psychiatric diseases, people with no legal; capacity or
             people with limited capacity for civil conduct;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TAO LI, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sichuan Cancer Hospital and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TAO LI, MD, PhD</last_name>
    <phone>86-18908178818</phone>
    <email>litaoxmf@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital &amp; Institute</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TAO , LI</last_name>
      <phone>86-18908178818</phone>
      <email>litaoxmf@163.com</email>
    </contact>
    <investigator>
      <last_name>Chonghua Xie, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liangfang Shen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Li, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiahua Wang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ligang Xing, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guangying Zhu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuchai Zhu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Cancer Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>LI TAO</investigator_full_name>
    <investigator_title>Section Head</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

